Novel Oncology Endpoints Take Time, Require Broad Outreach, US FDA Says

 
• By cole werble
  
Global access to some products could slow if the FDA accepts novel endpoints like ctDNA before other regulators. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from United States